Real-world data (RWD) is no longer an afterthought—it’s being integrated earlier in the development lifecycle to:
✅ Map disease progression
✅ Inform trial design
✅ Recruit patients
✅ Benchmark therapies
✅ Identify gaps in access and representation
This shift is particularly impactful in rare and heterogeneous cancers, where traditional trials often struggle with participant diversity and enrollment challenges.
A standout example is the use of circulating tumor DNA (ctDNA) to monitor minimal residual disease (MRD). Sequencing panels applied in real-world settings are now guiding treatment decisions in real time—offering early indicators of therapeutic resistance or efficacy. MRD tracking is emerging as a powerful source of real-world evidence (RWE), helping clinicians personalize care with greater precision.
At Clinakos Inc, we’re advancing this transformation through our innovative Integrated Patient Data™ and Medically Smart AI™, integrating real-world data into our AI-powered platforms to support researchers and clinicians:
- Connect fragmented data for a holistic patient view
- Generate actionable insights for earlier, smarter interventions
- Deliver better, more personalized outcomes in oncology
As RWE transitions from periphery to the core of oncology research and development, we @Clinakos are ready to accelerate this revolution.
Read the whole article here
Reach out to us to learn more at https://lnkd.in/gp3gUmXc
Follow us at Clinakos Inc
